You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
葛蘭素史克將從mRNA疫苗專利糾紛中獲得5億美元收益
CureVac與輝瑞(PFE.US)及BioNTech(BNTX.US)就mRNA疫苗長期專利糾紛達成和解,CureVac的前合作夥伴葛蘭素史克將獲得高達5億美元的收入,以及未來疫苗銷售額1%的專利使用費。 今次和解正值BioNTech尋求以約12.5億美元完成對收購CureVac之際,葛蘭素史克將獲得3.7億美元的預付款,並在收購完成後再獲得1.3億美元。 不過,雖然今次和解協議結束CureVac與輝瑞及BioNTech的訴訟,但葛蘭素史克表示,將繼續對BioNTech及輝瑞就侵犯專利提出訴訟。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account